市場調査レポート

商品コード

1624061

バイオ医薬品CMO・CROの市場規模・シェア・成長分析 (供給源別、サービスの種類別、製品別、地域別)：産業予測 (2025～2032年)

Biopharmaceutical CMO & CRO Market Size, Share, Growth Analysis, By Source (Mammalian, Non-mammalian), By Service Type (Contract Manufacturing, Contract Research), By Product, By Region - Industry Forecast 2025-2032

出版日: 2025年01月02日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 763,518円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 893,172円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,022,826円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界のバイオ医薬品CMO・CROの市場規模は、2023年に324億米ドルと評価され、2024年の343億1,000万米ドルから2032年には542億8,000万米ドルに成長し、予測期間中 (2025-2032年) のCAGRは5.9%に達する見通しです。

バイオ医薬品セクターは急速な成長を遂げ、現在では世界の医薬品市場の20%以上を占めています。この拡大は、COVID-19の大流行と、業界内の生産性と効率性の向上を目指した投資の増加から大きな影響を受けています。バイオ製薬企業が資源集約的なプロセスのアウトソーシングに注力する中、医薬品製造業務受託機関 (CMO) や医薬品開発業務受託機関 (CRO) への依存度が急上昇し、そのサービスに対する有利な需要が生まれています。抗生物質製造におけるオーストラリア政府のサンド社への投資のような最近の協力関係は、革新的で統合されたソリューションへのこのセクターのコミットメントをさらに際立たせています。この分野でのM&Aにより、CMOは包括的なバイオ加工サービスを提供できるようになり、迅速な製品開発と市場参入に不可欠なパートナーとなっています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情勢

上位5社の比較
主要企業の市場ポジショニング (2024年)
主要企業が採用した戦略
市場の近年の動向
主要企業の市場シェア (2024年)
主要企業のプロファイル
- 企業概要
- 製品ポートフォリオ分析
- セグメント別シェア分析
- 収益の前年比比較 (2022～2024年)

主要企業のプロファイル

Lonza Group (スイス)
Thermo Fisher Scientific (米国)
Catalent (米国)
WuXi Biologics (中国)
Samsung Biologics (韓国)
IQVIA (米国)
Syneos Health (米国)
ICON Plc (アイルランド)
Medpace Holdings (米国)
Charles River Laboratories (米国)
PPD (米国)
Labcorp Drug Development (米国)
Parexel International (米国)
PRA Health Sciences (米国)
BioNTech SE (Germany)
Moderna, Inc. (米国)
Gilead Sciences (米国)
Regeneron Pharmaceuticals (米国)
Vertex Pharmaceuticals (米国)
Amgen Inc. (米国)

結論と推奨事項

Product Code: SQSG35H2018

Global Biopharmaceutical CMO & CRO Market size was valued at USD 32.4 billion in 2023 and is poised to grow from USD 34.31 billion in 2024 to USD 54.28 billion by 2032, growing at a CAGR of 5.9% during the forecast period (2025-2032).

The biopharmaceutical sector has seen rapid growth, now comprising over 20% of the global pharmaceutical market, largely driven by increasing consumer demand for therapeutic solutions. This expansion has been significantly influenced by the COVID-19 pandemic and rising investments aimed at enhancing productivity and efficiency within the industry. As biopharma companies focus on outsourcing resource-intensive processes, the reliance on Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) has surged, creating a lucrative demand for their services. Recent collaborations, such as the Australian government's investment with Sandoz in antibiotic manufacturing, further highlight the sector's commitment to innovative, integrated solutions. Mergers and acquisitions within this space enable CMOs to deliver comprehensive bioprocessing services, making them essential partners for expedited product development and market entry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biopharmaceutical CMO & CRO market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biopharmaceutical CMO & CRO Market Segmental Analysis

Global Biopharmaceutical CMO and CRO Market is segmented by Source, Service Type, Product and region. Based on Source, the market is segmented into Mammalian and Non-mammalian. Based on Service Type, the market is segmented into Contract Manufacturing and Contract Research. Based on Product, the market is segmented into Biologics and Biosimilars. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Biopharmaceutical CMO & CRO Market

The global biopharmaceutical CMO and CRO market is poised for rapid growth due to the integration of innovative bioprocessing technologies and the adoption of single-use systems. Recently, the industry has experienced numerous consolidations aimed at enhancing competitiveness and operational efficiency. As new therapies and bioprocessing methods emerge, contract bioproducers face increasing pressure to adapt to shifting market demands. This has led to the development of alternative business models that cater to diverse stakeholder needs. Furthermore, the implementation of single-use technologies within manufacturing facilities is expected to significantly enhance production capabilities, thus creating new growth opportunities within the market throughout the forecast period.

Restraints in the Global Biopharmaceutical CMO & CRO Market

The Global Biopharmaceutical CMO and CRO market is currently facing significant restraints that hinder its growth, primarily due to high initial investments and limited outsourcing opportunities. Unlike the pharmaceutical CMO sector, which enjoys profit margins between 5% and 10%, the biopharmaceutical CMO market boasts margins exceeding 30%. However, the hefty investments required for advanced manufacturing facilities and cutting-edge equipment needed to accelerate biomanufacturing processes are impeding progress. Additionally, the reluctance of established biopharmaceutical companies to outsource further restricts market expansion. Complications arising from the regulatory environment and intricate contract negotiations, particularly concerning intellectual property rights, warranties, and confidentiality, exacerbate these challenges.

Market Trends of the Global Biopharmaceutical CMO & CRO Market

The Global Biopharmaceutical CMO & CRO market is witnessing a significant trend towards new product development, driven by increasing biopharmaceutical innovation and rising demand for specialized therapeutic solutions. As biopharma companies focus on accelerating drug discovery and reducing time-to-market, CMOs and CROs are enhancing their capabilities in advanced analytics, biologics production, and regulatory expertise. This trend is further fueled by collaborative partnerships and investments in technology, enabling companies to bring cutting-edge therapies, including personalized medicine and biologics, to fruition. Overall, the emphasis on new product development is expected to positively impact growth and competitiveness within the biopharmaceutical sector.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technological Advancement

Global Biopharmaceutical CMO & CRO Market Size by Source & CAGR (2025-2032)

Market Overview
Mammalian
Non-mammalian

Global Biopharmaceutical CMO & CRO Market Size by Service Type & CAGR (2025-2032)

Market Overview
Contract Manufacturing
- Process Development
- Downstream
- Upstream
- Fill & Finish Operations
- Analytical & QC Studies
- Packaging
Contract Research
- Oncology
- Inflammation & Immunology
- Cardiology
- Neuroscience
- Others

Global Biopharmaceutical CMO & CRO Market Size by Product & CAGR (2025-2032)

Market Overview
Biologics
- Monoclonal antibodies (MAbs)
- Recombinant Proteins
- Vaccines
- Antisense, RNAi, & Molecular Therapy
- Others
Biosimilars

Global Biopharmaceutical CMO & CRO Market Size & CAGR (2025-2032)

North America (Source, Service Type, Product)
- US
- Canada
Europe (Source, Service Type, Product)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Source, Service Type, Product)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Source, Service Type, Product)
- Brazil
- Rest of Latin America
Middle East & Africa (Source, Service Type, Product)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Lonza Group (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalent (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi Biologics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Samsung Biologics (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IQVIA (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Syneos Health (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ICON Plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medpace Holdings (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Charles River Laboratories (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PPD (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Labcorp Drug Development (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Parexel International (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PRA Health Sciences (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moderna, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

バイオ医薬品CMO・CROの市場規模・シェア・成長分析 (供給源別、サービスの種類別、製品別、地域別)：産業予測 (2025～2032年)

Biopharmaceutical CMO & CRO Market Size, Share, Growth Analysis, By Source (Mammalian, Non-mammalian), By Service Type (Contract Manufacturing, Contract Research), By Product, By Region - Industry Forecast 2025-2032

目次

イントロダクション

分析手法

エグゼクティブサマリー

市場力学と展望

市場の主な考察

世界のバイオ医薬品CMO・CROの市場規模・CAGR：供給源別 (2025～2032年)

世界のバイオ医薬品CMO・CROの市場規模・CAGR：サービスの種類別 (2025～2032年)

世界のバイオ医薬品CMO・CROの市場規模・CAGR：製品別 (2025～2032年)

世界のバイオ医薬品CMO・CROの市場規模・CAGR (2025～2032年)